India’s exports of active pharmaceutical ingredients (APIs) surpassed imports in the financial year 2024–25, reaching more than ₹41,500 crore and marking a significant milestone for the country’s pharmaceutical sector.
The achievement reflects growing domestic manufacturing capacity and increasing global demand for Indian-made pharmaceutical raw materials. APIs are the core components used in the production of medicines, and India has been working to strengthen its capabilities in this segment to reduce reliance on overseas supplies.
Industry data shows that rising export volumes were driven by strong demand from markets in North America, Europe and emerging economies. Indian manufacturers have also benefited from expanded production capacity and improved regulatory compliance, enabling them to access more international markets.
The shift to a net export position is seen as an important step for the country’s pharmaceutical industry, which has historically relied on imports—particularly from China—for certain key ingredients. Government initiatives aimed at boosting domestic API manufacturing, including financial incentives and infrastructure support, have encouraged companies to increase local production.
Pharmaceutical industry representatives say the trend could further strengthen India’s position as a global supplier of pharmaceutical inputs while supporting the country’s broader ambition to build a more resilient drug manufacturing supply chain. Continued investments in manufacturing and research are expected to sustain export growth in the coming years.